Dec 17 2009
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that Cancer Research UK’s Drug Development Office – the drug development arm of the world’s largest independent organization dedicated to cancer research – is standardizing on Phase Forward’s InForm™ Global Trial Management solution to support its diverse portfolio of early-stage clinical trials. The announcement marks a multi-year agreement between Phase Forward and the prestigious research organization.
Cancer Research’s Drug Development Office plans to use the InForm data capture solution to manage up to ten highly specialized trials each year. The organization has pioneered the development of some of the most novel anti-cancer treatments in the marketplace, such as temozolomide, widely recognized as the gold standard treatment for most cases of glioma – the most common form of brain cancer.
In late spring, Cancer Research UK’s Drug Development Office initiated a formal evaluation process as part of its Clinical Operations ReEngineering (CORE) project, an initiative that aims to deliver high-quality data faster, with the goal of beating cancer. As part of this initiative, the organization set out to select a best-of-breed electronic data capture (EDC) product, working with multiple vendors to find the ideal business and technical partner to meet the organization’s requirements.
After an extensive evaluation, the Drug Development Office selected Phase Forward’s InForm solution, based on the partnership approach and flexibility demonstrated by Phase Forward’s global services team. Other key factors included technical strength and scalability of the product, the company’s broad experience with oncology trials and the availability of investigators trained in using InForm.
“Information is key to our success in managing early stage clinical trials, so it is vital that we invest in the technology to support this important work,” said Dr. Nigel Blackburn, director of Cancer Research UK’s Drug Development Office. “We were particularly impressed with Phase Forward’s commitment to addressing our requirements, as well as the company’s experience in developing the data capture tools to manage these trials.”
“Cancer Research UK is one of the most respected organizations in the world, advancing the cause of cancer prevention, diagnosis and treatment,” said Bob Weiler, chairman and CEO, Phase Forward. “We’re honored to work with their dedicated team of professionals to help deliver the next generation of cancer treatments.”
The organization’s first study using the InForm solution will compare two treatments for metastatic prostate cancer.
http://www.phaseforward.com/
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths